Her2 Mutated News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Japan’s Ministry of Health, Labour, and Welfare has approved fam-trastuzumab deruxtecan-nxki for use in adult patients with unresectable advanced or recurrent, HER2-mutant non–small cell lung cancer that has progressed following chemotherapy.

Daiichi sankyoWataru takasakiRd divisionJapan ministry of healthMasahiro tsuboiTrastuzumab deruxtecanHer2 mutatedNon small cell lung cancerPhase 2 destiny lung02 trial